This is a medicine used to treat certain types of cancer that cause bone problems. It helps stop the body from breaking down bone tissue, which can relieve pain and lower calcium levels. It's usually given as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Aredia (Pamidronate) for Multiple Myeloma?
Pamidronate is a prescription bone medicine given through a vein. It was first sold under the brand name Aredia; in the US today it is supplied mainly as generic pamidronate injection. It belongs to a group of medicines called bisphosphonates, which slow the breakdown of bone. It has three approved uses in adults. The first is high blood calcium caused by cancer (hypercalcemia of malignancy), when levels are moderate or severe; it is given together with intravenous fluids. The second is bone damage from cancer: lytic bone metastases from breast cancer, which are areas where cancer has eaten away bone, and the bone lesions of multiple myeloma, a blood cancer. Here it is given alongside the cancer treatment itself, not instead of it. The third is moderate to severe Paget's disease of bone, a condition in which bone is broken down and rebuilt too quickly, leaving it thickened but weaker. Specialists also use pamidronate off-label in osteogenesis imperfecta (brittle bone disease), including in children, although it is not labeled for children in the US. Zoledronic acid, a related bisphosphonate given as a shorter infusion, and denosumab, an injected antibody medicine, are common alternatives for cancer-related bone disease.
Bone is constantly remodeled. Cells called osteoclasts dissolve old bone, releasing calcium into the blood, while other cells lay down new bone. Some cancers push osteoclasts into overdrive, either by invading bone directly or by releasing substances that travel through the blood. Bone weakens, and so much calcium is released that blood levels climb. Pamidronate binds tightly to the mineral surface of bone and holds back osteoclast activity there. Less bone is broken down, so less calcium enters the blood, and weakened areas are less likely to fracture. In Paget's disease, slowing this runaway turnover lets bone markers settle toward normal. Because the drug is stored in bone and released slowly over weeks to years, a single infusion has a lasting effect.
Pamidronate is given only as a slow intravenous (IV) infusion by a nurse in a hospital, clinic or infusion center. The infusion takes hours, not minutes, because giving it too fast can harm the kidneys, and a single dose is never more than 90 mg. The schedule depends on the reason for treatment. For cancer-related high calcium it is usually a single infusion over 2 to 24 hours, given with IV fluids; if calcium rises again, it can be repeated after at least a week. For breast cancer that has spread to bone, it is typically given over 2 hours every 3 to 4 weeks, and for myeloma over 4 hours once a month, often for a year or two. For Paget's disease, a shorter infusion is given on 3 days in a row, and the course may be repeated later if the disease becomes active again. People receiving it for bone metastases, myeloma or Paget's disease are usually advised to take calcium and vitamin D by mouth each day, unless their calcium is already high. If an infusion appointment is missed, contact the care team to reschedule.
A mild fever or flu-like aches in the day or two after an infusion are common, particularly after the first dose, and usually pass on their own. Some people have redness, swelling or soreness where the IV was placed, or nausea, tiredness, headache or loss of appetite, though in people with cancer many of these overlap with the illness and its treatment. Pamidronate can lower blood levels of calcium, phosphate, magnesium and potassium, which is one reason for blood tests. Contact the care team promptly about muscle cramps or spasms, or tingling around the mouth, which can signal low calcium. Also call promptly about eye pain, redness or tearing, since the drug can rarely inflame the eye, and about severe bone, joint or muscle pain, which some people develop and which usually eases after stopping. Two uncommon problems build slowly. Osteonecrosis of the jaw is an area of jawbone that loses its blood supply and fails to heal; report painful or swollen gums, loosening teeth, numbness or a heavy feeling in the jaw, or a tooth socket that is not healing. New aching in the thigh or groin without an injury should also be checked, as it can come before an unusual fracture of the thighbone.
Kidney damage is the most important risk. Pamidronate leaves the body through the kidneys and can injure them, occasionally to the point of kidney failure. A blood test of kidney function (creatinine) is checked before every dose, and treatment is paused if it worsens. Risk is higher with existing kidney disease, dehydration and other medicines that strain the kidneys; in myeloma, combining it with thalidomide, a myeloma medicine, may add to the risk. The jaw risk is highest in people with cancer, particularly with tooth extractions, gum disease, poorly fitting dentures, or treatment with chemotherapy or steroids. A dental exam, with any needed extractions done before starting, good daily oral hygiene, and avoiding invasive dental work during treatment when possible all lower the risk. Tell any dentist that you receive pamidronate. Pamidronate should not be given to anyone who has had a significant allergic reaction to it or to another bisphosphonate, such as alendronate (Fosamax) or zoledronic acid. It may harm a developing baby, and because it stays in bone for years, anyone who is pregnant, may become pregnant, or is breastfeeding should discuss this before treatment. People who have had thyroid surgery can be more prone to low calcium.
For high calcium, blood levels usually begin to fall within a day or two and reach their lowest point over about a week. The effect wears off in days to weeks for many people, especially if the cancer itself is not controlled, so calcium is rechecked and treatment can be repeated. Pamidronate controls the calcium; it does not treat the cancer that is causing it. For bone damage from breast cancer or myeloma, the benefit is fewer fractures, less need for radiation or surgery to bone, and in some people less bone pain over months of regular infusions. In a key myeloma trial, about a quarter of people on pamidronate had such a bone complication over nine months, compared with about two in five on placebo; it did not lengthen survival. Treatment often continues for up to two years, with the schedule reviewed as the cancer responds. In Paget's disease, blood markers of bone turnover typically improve within about a month, though effects on pain and mobility have been less clear in studies. Throughout treatment, expect regular blood tests for kidney function, calcium and other minerals, and blood counts.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aredia (Pamidronate), what you've noticed, or ask the community a question.